glp-1 dementia news Can popular diabetes and weight-loss drugs slow vascular dementia? In New Dementia Trials, Ozempic's

WHAT'S INCLUDED

Patient Cost Sharing Library The Complex Web Behind Low Persistence Low persistence in GLP-1 therapy is rarely the result of a single factor

A large, retrospective study conducted by scientists at The University of Texas at San Antonio suggests that people taking glucagon-like peptide-1 (GLP-1) receptor agonists medications that are widely prescribed for metabolic disease have a significantly lower risk of developing colorectal cancer compared with those taking aspirin.

For optimal results, it's recommended to take two capsules daily with food, maintaining consistent use for at least 3-6 months

These changes are a key reason why fiber intake and digestive support are commonly recommended for people using GLP-1 medications.

The cohort comprised patients over 20 years old who were newly treated with glucose-lowering drugs between 1 January 2013 and 31 December 2021, and followed until 30 September 2022